ReviewMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
Beilschmiedia species: from chemistry to pharmacological values.
Review in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beilschmiedia (the family Lauraceae) is a large tropical genus containing species traditionally used to treat rheumatism, tumors, malaria, infections, and others. Despite extensive ethnomedicinal applications, a comprehensive evaluation of its phytochemistry and pharmacology remains limited. This review aims to consolidate current knowledge on the phytochemical diversity, biosynthetic and synthetic pathways, pharmacological potential, and chemical modifications of Beilschmiedia species. Relevant studies were retrieved from PubMed, Scopus, Web of Science, and Google Scholar up to September 2025 using "Beilschmiedia" as the main keyword. Eligible publications included original reports on phytochemical isolation, structure elucidation, biosynthetic studies, synthetic modification, and pharmacological evaluation, whereas botanical identifications were excluded. Over 240 compounds were characterized from 30 Beilschmiedia species, encompassing tetracyclic polyketides, alkaloids, terpenoids, phytosterols, lignans, neolignans, flavonoids, alkamides, and others. Endiandric acids and cyclobutane/oxetane-type neolignans, possessing unique skeletons, could be chemotaxonomic significance. Pharmacological studies have revealed diverse activities, such as cytotoxic, antimicrobial, antimalarial, antioxidant, anti-inflammatory, antidiabetic, and cholinesterase-inhibitory activities. Advances in biosynthesis, total synthesis, and semi-synthetic modification have facilitated the exploration of structure-activity relationships. Beilschmiedia represents a valuable reservoir of chemically novel and biologically active compounds. Future research should expand phytochemical surveys to underexplored species, integrate metabolomic and genomic approaches, and conduct advanced pharmacological studies, including in vivo validation and formulation development.
Indexed as
Identifiers
42446653What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.